Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a recent article he and his colleagues co-authored on X, adding:

“Very glad to contribute to this large (11 trials, 2500 pts) meta-analysis led by Guillermo Villacampa, now out in The Lancet Oncology.

Half of the patients had high HER2DX risk score and were found to have a significantly higher risk of recurrence, irrespective of pCR/RD.”

Title: HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis

Authors: Guillermo Villacampa, Tomás Pascual, Paolo Tarantino, Javier Cortés, José Perez-García, Antonio Llombart-Cussac, Pierfranco Conte, Mario Mancino, Valentina Guarneri, Maria Vittoria Dieci, Adrienne G Waks, Francesco Schettini, Fara Brasó-Maristany, Gaia Griguolo, Beatriz Alonso de Castro, Cristina Reboredo, Silvia Antolín, Coralia Bueno-Muiño, Isabel Echavarría, Sara López-Tarruella, Sara M Tolaney

Read the Full Article on The Lancet Oncology

Paolo Tarantino: Large Meta-Analysis on HER2DX and Survival Outcomes in Early-Stage HER2-Positive Breast Cancer